Copyright
©The Author(s) 2025.
World J Methodol. Mar 20, 2025; 15(1): 97171
Published online Mar 20, 2025. doi: 10.5662/wjm.v15.i1.97171
Published online Mar 20, 2025. doi: 10.5662/wjm.v15.i1.97171
Table 2 Epidemiological profiles and clinical features of 17 patients with restless head syndrome
| Parameter | N (17) (%) | |
| Age (years) (mean ± SD) | 41.6 (± 9.6) | |
| Sex (Male:Female) | 9:8 (1.2:1) | |
| Duration of illness (mo) | 53.9 ± 26.2 | |
| Presenting features or chief complaints | ||
| Headache | 12 (70.5) | |
| Dizziness | 5 (29.4) | |
| Leg pain | 3 (17.3) | |
| Backache | 2 (11.8) | |
| Generalized body pain | 2 (11.8) | |
| Clinical features | ||
| Lower legs discomforts | 17 (100) | |
| Headache | 14 (82.3) | |
| Arms discomforts | 12 (70.5) | |
| Backache | 6 (35.2) | |
| Dizziness | 5 (29.4) | |
| Generalized body pain | 3 (17.3) | |
| Insomnia | 16 (88.2) | |
| Met international restless legs syndrome study group criteria | 17 (100) | |
| Treatment (dopaminergic agents) | ||
| Pramipexole 0.125 to 0.250 mg daily | 8 (47.1) | |
| Levodopa/carbidopa (100/10 mg) | 5 (29.4) | |
| Ropinirole 0.50 mg daily | 4 (23.5) | |
- Citation: Prakash S, Vadodaria V, Chawda N, Shah CS, Prakash A. Restless head syndrome: A retrospective study. World J Methodol 2025; 15(1): 97171
- URL: https://www.wjgnet.com/2222-0682/full/v15/i1/97171.htm
- DOI: https://dx.doi.org/10.5662/wjm.v15.i1.97171